Sample Page

Dexclamol (AY 24169) was an investigational new drug developed by McKenna and Harrison, Ltd. that was evaluated as a antipsychotic.[1][2][3][4] It acts as a dopamine receptor antagonist.[1]

See also

References

  1. ^ a b Humber LG, Bruderlein FT, Voith K (November 1975). “Neuroleptic agents of the benzocycloheptapyridoisoquinoline series. A hypothesis on their mode of interaction with the central dopamine receptor”. Molecular Pharmacology. 11 (6): 833–840. doi:10.1016/S0026-895X(25)10694-9. PMID 1239657.
  2. ^ Elks J, Ganellin CR, eds. (1990). Dictionary of Drugs. Springer US. doi:10.1007/978-1-4757-2085-3. ISBN 978-1-4757-2087-7.
  3. ^ Castañer J, Paton DM (1976). “Dexclamol hydrochloride”. Drugs of the Future. 1 (8): 366. doi:10.1358/dof.1976.001.08.1002521.
  4. ^ US 3657250, Bruderlein FT, Humber LG, ”Benzocycloheptaisoquinoline derivatives”, assigned to Ayerst Mckenna and Harrison Inc.